(19)
(11) EP 4 771 381 A1

(12)

(43) Date of publication:
08.07.2026 Bulletin 2026/28

(21) Application number: 24769202.3

(22) Date of filing: 26.08.2024
(51) International Patent Classification (IPC): 
G01N 30/96(2006.01)
G01N 27/447(2006.01)
G01N 33/15(2006.01)
G01N 21/59(2006.01)
B01D 15/36(2006.01)
G01N 30/86(2006.01)
G01N 30/88(2006.01)
(52) Cooperative Patent Classification (CPC):
G01N 2030/8831; G01N 30/96; B01D 15/362; G01N 30/8679; G01N 33/15; G01N 27/447; B01D 15/327
(86) International application number:
PCT/US2024/043843
(87) International publication number:
WO 2025/049384 (06.03.2025 Gazette 2025/10)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(30) Priority: 31.08.2023 US 202363579844 P

(71) Applicant: Amgen Inc.
Thousand Oaks, California 91320-1799 (US)

(72) Inventors:
  • WANG, Sean
    Thousand Oaks, California 91320-1799 (US)
  • HAPUARACHCHI, Suminda
    Thousand Oaks, California 91320-1799 (US)
  • ZHANG, Qingchun
    Thousand Oaks, California 91320-1799 (US)
  • KUHNS, Scott Thomas
    Thousand Oaks, California 91320-1799 (US)
  • HE, Lidong
    Thousand Oaks, California 91320-1799 (US)
  • GUAN, Xiaoyan
    Thousand Oaks, California 91320-1799 (US)

(74) Representative: Dörries, Hans Ulrich 
df-mp Patentanwälte Rechtsanwälte PartG mbB Theatinerstraße 16
80333 München
80333 München (DE)

   


(54) METHODS FOR ANALYZING ANTIBODY CO-FORMULATIONS